The Star Beacon; Ashtabula, Ohio

World, nation, state

February 23, 2013

FDA approves new breast cancer drug

WASHINGTON — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.

The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.

Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.

“This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it’s very kind and gentle on the patients — there’s no hair loss, no nausea, no vomiting,” said Dr. Melody Cobleigh of Rush University Medical Center. “It’s a revolutionary way of treating cancer.”

Cobleigh helped conduct the key studies of the drug at the Chicago facility.

The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.

The approval will help Roche’s Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.

Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.

Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.

FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer

Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.

Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug’s sales.

Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.

 

1
Text Only
World, nation, state
  • Troubled childhoods may prompt men to volunteer for military service

    In the era of the all-volunteer U.S. military, men who served are more than twice as likely as those who never did to have been sexually abused as children and to have grown up around domestic violence and substance abuse, a new study has found.

    July 24, 2014

  • As poverty continues to rise, fewer Ohioans are receiving state aid

    The number of Ohioans receiving public assistance continues to drop even while poverty increases, raising questions about how the state helps the poor.

    July 24, 2014

  • ’Saltwater’ from fracking spill much different from ocean water

    In early July, a million gallons of salty drilling waste spilled from a pipeline onto a steep hillside in western North Dakota’s Fort Berthold Reservation. The waste — a byproduct of oil and gas production — has now reached a tributary of Lake Sakakawea, which provides drinking water to the reservation.

    July 24, 2014

  • 40 bodies from jet solemnly returned to Dutch soil

    Victims of the Malaysian jetliner shot down over Ukraine returned at last Wednesday to Dutch soil in 40 wooden coffins, solemnly and gently carried to 40 identical hearses, flags at half-staff flapping in the wind.

    July 23, 2014

  • U.S. pushes for truce as Gaza battle rages

    The United States announced signs of progress in cease-fire talks Wednesday, but prospects for a quick end to the fighting were dim as Palestinian families fled fierce battles in southern Gaza and the death toll rose to more than 700 Palestinians and 34 Israelis.

    July 23, 2014

  • GROUNDED U.S., other countries ban flights to and from Israel

    A Hamas rocket exploded Tuesday near Israel’s main airport, prompting a ban on all flights from the U.S. and many from Europe and Canada as aviation authorities responded to the shock of seeing a civilian jetliner shot down over Ukraine.

    July 23, 2014

  • REPORT: Retaliation by supervisors common at VA

    A pharmacy supervisor at the VA was placed on leave after complaining about errors and delays in delivering medications to patients at a hospital in Palo Alto, California. In Pennsylvania, a doctor was removed from clinical work after complaining that on-call doctors were refusing to go to a VA hospital in Wilkes-Barre.

    July 22, 2014

  • Veteran's Ducks Iraq vet cited for owning 14 therapeutic pet ducks

    An Army veteran who hurt his back during the Iraq War is worried a citation will result in him losing his 14 pet ducks, which he says are therapeutic.

    July 21, 2014 1 Photo

  • Stacked Apartment.jpg New York building shows how mod design stacks up as cool

    In a city piled high with ambitious architecture, a seven-floor structure off the beaten path boasts a distinction of its own: It’s billed as the first multistory, modular-built apartment building to open in the nation’s apartment capital.

    July 21, 2014 1 Photo

  • Scores dead in first major ground battle in Gaza

    The first major ground battle in two weeks of Israel-Hamas fighting exacted a steep price Sunday: It killed 65 Palestinians and 13 Israeli soldiers and forced thousands of terrified Palestinian civilians to flee their neighborhood, reportedly used to launch rockets at Israel and now devastated by the fighting.

    July 21, 2014

House Ads
Parade
Magazine

Click HERE to read all your Parade favorites including Hollywood Wire, Celebrity interviews and photo galleries, Food recipes and cooking tips, Games and lots more.
AP Video